Literature DB >> 31486842

Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma.

David A Braun1, Yuko Ishii2, Alice M Walsh2, Eliezer M Van Allen1, Catherine J Wu1, Sachet A Shukla1, Toni K Choueiri1.   

Abstract

Entities:  

Year:  2019        PMID: 31486842      PMCID: PMC6735411          DOI: 10.1001/jamaoncol.2019.3158

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  65 in total

1.  Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.

Authors:  Sarah Abou Alaiwi; Amin H Nassar; Wanling Xie; Ziad Bakouny; Jacob E Berchuck; David A Braun; Sylvan C Baca; Pier Vitale Nuzzo; Ronan Flippot; Tarek H Mouhieddine; Liam F Spurr; Yvonne Y Li; Taiwen Li; Abdallah Flaifel; John A Steinharter; Claire A Margolis; Natalie I Vokes; Heng Du; Sachet A Shukla; Andrew D Cherniack; Guru Sonpavde; Robert I Haddad; Mark M Awad; Marios Giannakis; F Stephen Hodi; X Shirley Liu; Sabina Signoretti; Cigall Kadoch; Matthew L Freedman; David J Kwiatkowski; Eliezer M Van Allen; Toni K Choueiri
Journal:  Cancer Immunol Res       Date:  2020-04-22       Impact factor: 11.151

2.  Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research.

Authors:  Toni K Choueiri; Michael B Atkins; Ziad Bakouny; Maria I Carlo; Charles G Drake; Eric Jonasch; Payal Kapur; Bryan Lewis; W Marston Linehan; Michael J Mitchell; Sumanta K Pal; Kevin Pels; Susan Poteat; W Kimryn Rathmell; Brian I Rini; Sabina Signoretti; Nizar Tannir; Robert Uzzo; Christopher G Wood; Hans J Hammers
Journal:  J Natl Cancer Inst       Date:  2021-03-01       Impact factor: 13.506

Review 3.  Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma.

Authors:  Kyrollis Attalla; Stanley Weng; Martin H Voss; A Ari Hakimi
Journal:  Urol Clin North Am       Date:  2020-06-10       Impact factor: 2.241

4.  Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma.

Authors:  Ivan Pourmir; Johanna Noel; Audrey Simonaggio; Stéphane Oudard; Yann-Alexandre Vano
Journal:  World J Urol       Date:  2021-01-02       Impact factor: 4.226

5.  Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.

Authors:  Lewis Au; Emine Hatipoglu; Marc Robert de Massy; Kevin Litchfield; Gordon Beattie; Andrew Rowan; Desiree Schnidrig; Rachael Thompson; Fiona Byrne; Stuart Horswell; Nicos Fotiadis; Steve Hazell; David Nicol; Scott T C Shepherd; Annika Fendler; Robert Mason; Lyra Del Rosario; Kim Edmonds; Karla Lingard; Sarah Sarker; Mary Mangwende; Eleanor Carlyle; Jan Attig; Kroopa Joshi; Imran Uddin; Pablo D Becker; Mariana Werner Sunderland; Ayse Akarca; Ignazio Puccio; William W Yang; Tom Lund; Kim Dhillon; Marcos Duran Vasquez; Ehsan Ghorani; Hang Xu; Charlotte Spencer; José I López; Anna Green; Ula Mahadeva; Elaine Borg; Miriam Mitchison; David A Moore; Ian Proctor; Mary Falzon; Lisa Pickering; Andrew J S Furness; James L Reading; Roberto Salgado; Teresa Marafioti; Mariam Jamal-Hanjani; George Kassiotis; Benny Chain; James Larkin; Charles Swanton; Sergio A Quezada; Samra Turajlic
Journal:  Cancer Cell       Date:  2021-10-28       Impact factor: 31.743

6.  Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma.

Authors:  Ritesh R Kotecha; Erika Gedvilaite; Ryan Ptashkin; Andrea Knezevic; Samuel Murray; Ian Johnson; Natalie Shapnik; Darren R Feldman; Maria I Carlo; Neil J Shah; Marisa Dunigan; Kety Huberman; Ryma Benayed; Ahmet Zehir; Michael F Berger; Marc Ladanyi; Dana W Y Tsui; Robert J Motzer; Chung-Han Lee; Martin H Voss
Journal:  JCO Precis Oncol       Date:  2022-07

7.  [Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].

Authors:  C P Qin; Y X Song; M T Ding; F Wang; J X Lin; W B Yang; Y Q DU; Q Li; S J Liu; T Xu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-08-18

8.  Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.

Authors:  Kevin Bi; Meng Xiao He; Ziad Bakouny; Abhay Kanodia; Sara Napolitano; Jingyi Wu; Grace Grimaldi; David A Braun; Michael S Cuoco; Angie Mayorga; Laura DelloStritto; Gabrielle Bouchard; John Steinharter; Alok K Tewari; Natalie I Vokes; Erin Shannon; Maxine Sun; Jihye Park; Steven L Chang; Bradley A McGregor; Rizwan Haq; Thomas Denize; Sabina Signoretti; Jennifer L Guerriero; Sébastien Vigneau; Orit Rozenblatt-Rosen; Asaf Rotem; Aviv Regev; Toni K Choueiri; Eliezer M Van Allen
Journal:  Cancer Cell       Date:  2021-03-11       Impact factor: 31.743

Review 9.  The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments.

Authors:  Javier C Angulo; Claudia Manini; Jose I López; Angel Pueyo; Begoña Colás; Santiago Ropero
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

10.  Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma.

Authors:  Xiaomao Yin; Zaoyu Wang; Jianfeng Wang; Yunze Xu; Wen Kong; Jin Zhang
Journal:  Oncoimmunology       Date:  2021-06-30       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.